



2024年3月期 決算参考資料

Financial Data for FY2024

The FY2024, the year ended March 31, 2024

April 1, 2023 - March 31, 2024

1. 連結決算概要 / Consolidated Financial Summary	2
2. セグメント別情報 / Information by Business Segment	
(1) 医療分野 / Medical Business	3,4,5
ESD (Endoscopic Solutions Division)・TSD (Therapeutic Solutions Division)	
(2) その他 / Others	6
(3) 全社消去 / Corporate Expenses	6
(4) 非継続事業（科学事業） / Discontinued Operation (Scientific Solutions Business)	6
3. 投資他 / Expenditures etc.	7
4. 連結キャッシュフロー計算書 / Consolidated Statement of Cash Flows	7
5. 連結財政状態計算書 / Consolidated Statement of Financial Position	8
6. 会社概要 / Corporate Outline	9

(本資料における留意点について)

(Notes regarding this material)

・本資料のうち、業績見通し等は、現在入手可能な情報による判断および仮定に基づいたものであり、判断や仮定に内在する不確定な要素および今後の事業運営や内外の状況変化等による変動可能性に照らし、実際の業績等が目標と大きく異なる可能性があります。

・また、これらの情報は、今後予告なしに変更されることがあります。従いまして、本情報及び資料の利用は、他の方法により入手された情報とも照合確認し、利用者の判断によって行ってくださいようお願い致します。

・本資料利用の結果生じたいかなる損害についても、当社は一切責任を負いません。

・科学事業の譲渡に関する正式契約の締結に伴い、2023年3月期第2四半期連結会計期間より、科学事業を非継続事業に分類しています。

これに伴い、過去に開示した以下の数値も組み替えて表示しています。

連結損益計算書：「2023年3月期第1四半期（3カ月）」

連結キャッシュフロー計算書：「2023年3月期第1四半期（3カ月）」

・2023年4月に非継続事業（エビデント）の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益を2024年3月期第1四半期連結会計期間に計上しています。

・This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.

・Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.

・Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.

・Following the conclusion of definitive agreement for divestiture of Scientific Solutions Business, Scientific Solutions Business is categorized as a discontinued operation, effective Q2 of FY2023. Accordingly, figures for below accounting periods are restated.

Consolidated Statements of Profit or Loss: FY2023Q1 (3M)

Consolidated Statement of cash flows: FY2023Q1 (3M)

・Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024Q1.

1. 連結決算概要 / Consolidated Financial Summary

■ 連結損益計算書概要 / Summary of Consolidated Statements of Profit or Loss

百万円 (¥ million)	FY2023					FY2024					FY2025
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Forecast
売上高 Revenue	192,265	224,795	224,485	240,378	881,923	207,723	228,921	239,070	260,496	936,210	1,021,000
売上原価 Cost of sales	66,544	72,990	68,287	77,253	285,074	70,497	77,710	76,074	86,806	311,087	322,000
売上総利益 Gross profit	125,721	151,805	156,198	163,125	596,849	137,226	151,211	162,996	173,690	625,123	699,000
販売費及び一般管理費 S.G.A. expenses	96,018	102,517	107,550	114,462	420,547	108,770	112,863	119,274	132,324	473,231	501,000
その他の収益および費用等 Other income and expenses etc.	14,818	-206	321	-4,626	10,307	-5,980	-56,035	-9,476	-36,803	-108,294	-21,000
営業利益 Operating profit	44,521	49,082	48,969	44,037	186,609	22,476	-17,687	34,246	4,563	43,598	177,000
調整後営業利益 Adjusted operating profit	29,740	49,622	48,767	48,664	176,793	28,267	38,303	43,602	41,362	151,534	198,500
金融収益および費用 Finance income and costs	-2,473	-1,809	1,080	-1,113	-4,315	-2,766	-2,981	-270	-1,727	-7,744	-6,000
税引前利益 Profit before tax	42,048	47,273	50,049	42,924	182,294	19,710	-20,668	33,976	2,836	35,854	171,000
法人所得税費用 Income taxes	14,158	5,637	13,956	10,553	44,304	6,224	4,308	14,997	-16,648	8,881	50,000
継続事業からの当期利益 Profit from continuing operations	27,890	41,636	36,093	32,371	137,990	13,486	-24,976	18,979	19,484	26,973	121,000
非継続事業からの当期利益(損失) Profit (loss) from discontinued operation	-2,968	382	5,336	2,873	5,623	227,128	1,021	-63	-12,130	215,956	-
当期利益(損失) Profit (loss)	24,922	42,018	41,429	35,244	143,613	240,614	-23,955	18,916	7,354	242,929	121,000
親会社の所有者に帰属する当期利益(損失) Profit (loss) attributable to owners of parent	24,860	41,976	41,381	35,215	143,432	240,560	-24,264	18,916	7,354	242,566	121,000
売上総利益率 Gross profit ratio	65.4%	67.5%	69.6%	67.9%	67.7%	66.1%	66.1%	68.2%	66.7%	66.8%	68.5%
販管費率 S.G.A. ratio	49.9%	45.6%	47.9%	47.6%	47.7%	52.4%	49.3%	49.9%	50.8%	50.5%	49.1%
営業利益率 Operating profit margin	23.2%	21.8%	21.8%	18.3%	21.2%	10.8%	-	14.3%	1.8%	4.7%	17.3%
調整後営業利益率 Adjusted operating margin	15.5%	22.1%	21.7%	20.2%	20.1%	13.6%	16.7%	18.2%	15.9%	16.2%	19.4%
継続事業からの当期利益率 Profit from continuing operations margin	14.5%	18.5%	16.1%	13.5%	15.7%	6.5%	-	7.9%	7.5%	2.9%	11.9%
ROE					24.9%					34.7%	
EBITDA	60,287	65,899	65,493	58,522	250,201	39,089	-1,406	50,487	21,368	109,538	245,000
EBITDAマージン EBITDA margin	31.4%	29.3%	29.2%	24.3%	28.4%	18.8%	-	21.1%	8.2%	11.7%	24.0%

*「その他の収益および費用等」は、持分法による投資損益・その他の収益・その他の費用の合算です。

"Other income and expenses etc." in the above table is the sum of share of profit (loss) of investments accounted for using equity method, other income, and other expenses.

* FY2023Q2より科学事業を非継続事業に分類しています。非継続事業からの利益は継続事業と区分し、「売上高」から「継続事業からの当期利益」までは継続事業の金額を表示しています。

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, profit from discontinued operation is presented separately from the profit from continuing operations. From "revenue" to "profit from continuing operations" in the above table are amounts related to continuing operations only.

*2023年4月に非継続事業（エビデント）の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益をFY2024Q1に計上しています。

Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024Q1.

■ 為替 / Foreign exchange

円 (¥)	FY2023					FY2024					FY2025
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Forecast
円/USD (期中平均レート) Yen/U.S. dollar (Average rate)	129.57	138.37	141.59	132.34	135.47	137.37	144.62	147.89	148.61	144.62	151.00
円/EUR (期中平均レート) Yen/Euro (Average rate)	138.12	139.34	144.30	142.10	140.97	149.47	157.30	159.11	161.31	156.80	163.00
円/CNY (期中平均レート) Yen/Renminyuan (Average rate)	19.58	20.19	19.87	19.34	19.75	19.56	19.94	20.44	20.63	20.14	21.00

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
売上高に対する為替影響額 FX Impact on revenue	19,482	30,228	29,050	19,621	98,381	8,278	9,609	11,032	22,485	51,404
営業利益に対する為替影響額 FX Impact on operating profit	7,934	13,168	12,989	10,254	44,345	4,548	-1,125	3,446	5,410	12,279

*上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

■ 為替感応度 (年間) / Foreign exchange sensitivity (Annual basis)

億円 (¥ 100 million)	売上高	営業利益
	Revenue	Operating profit
ドル (1円あたり) U.S. dollar (Per 1JPY)	26	5
ユーロ (1円あたり) Euro (Per 1JPY)	16	5
人民元 (1円あたり) Renminyuan (Per 1JPY)	52	27

*上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

*上表の数値はFY2024Q4実績より算出しています。 / Amounts in the above table are calculated based on FY2024Q4 results.

2. セグメント別情報 / Information by Business Segment

(1) 医療分野 / Medical Business

■ ESD 損益 / Revenue and Operating profit of ESD

百万円 (¥ million)	FY2023					FY2024					FY2025 Forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	
売上高 Revenue	116,857	141,615	140,518	152,833	551,823	127,138	143,729	148,449	167,301	586,617	645,000
営業利益 Operating profit	24,834	44,065	41,804	42,066	152,769	22,177	28,732	32,671	21,104	104,684	162,000
その他の損益 Other income and expenses	-1,179	-236	-908	-1,503	-3,826	-3,390	-4,423	-4,133	-16,473	-28,419	-12,500
調整後営業利益 Adjusted operating profit	26,013	44,301	42,712	43,569	156,595	25,567	33,155	36,804	37,577	133,103	174,500
営業利益率 Operating profit margin	21.3%	31.1%	29.7%	27.5%	27.7%	17.4%	20.0%	22.0%	12.6%	17.8%	25.1%
調整後営業利益率 Adjusted operating margin	22.3%	31.3%	30.4%	28.5%	28.4%	20.1%	23.1%	24.8%	22.5%	22.7%	27.1%
売上高対前年比 Revenue (YoY)						8.8%	1.5%	5.6%	9.5%	6.3%	10.0%
営業利益対前年比 Operating profit (YoY)						-10.7%	-34.8%	-21.8%	-49.8%	-31.5%	54.8%

■ TSD 損益 / Revenue and Operating profit of TSD

百万円 (¥ million)	FY2023					FY2024					FY2025 Forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	
売上高 Revenue	72,365	80,570	81,007	84,265	318,207	77,156	82,542	87,528	90,105	337,331	363,000
営業損益 Operating profit (loss)	13,357	16,431	18,328	15,576	63,692	9,681	-38,223	12,366	7,710	-8,466	54,500
その他の損益 Other income and expenses	-242	116	1,288	-1,751	-589	-1,899	-52,765	-3,831	-6,994	-65,489	-7,500
調整後営業利益 Adjusted operating profit	13,599	16,315	17,040	17,327	64,281	11,580	14,542	16,197	14,704	57,023	62,000
営業利益率 Operating profit margin	18.5%	20.4%	22.6%	18.5%	20.0%	12.5%	-	14.1%	8.6%	-	15.0%
調整後営業利益率 Adjusted operating margin	18.8%	20.2%	21.0%	20.6%	20.2%	15.0%	17.6%	18.5%	16.3%	16.9%	17.1%
売上高対前年比 Revenue (YoY)						6.6%	2.4%	8.0%	6.9%	6.0%	7.6%
営業利益対前年比 Operating profit (YoY)						-27.5%	-	-32.5%	-50.5%	-	-

■ 医療分野 損益 / Revenue and Operating profit of Medical Business

百万円 (¥ million)	FY2023					FY2024					FY2025 Forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	
売上高 Revenue	189,222	222,185	221,525	237,098	870,030	204,294	226,271	235,977	257,406	923,948	1,008,000
営業利益 Operating profit	38,191	60,496	60,132	57,642	216,461	31,858	-9,491	45,037	28,814	96,218	216,500
その他の損益 Other income and expenses	-1,421	-120	380	-3,254	-4,415	-5,289	-57,188	-7,964	-23,467	-93,908	-20,000
調整後営業利益 Adjusted operating profit	39,612	60,616	59,752	60,896	220,876	37,147	47,697	53,001	52,281	190,126	236,500
営業利益率 Operating profit margin	20.2%	27.2%	27.1%	24.3%	24.9%	15.6%	-	19.1%	11.2%	10.4%	21.5%
調整後営業利益率 Adjusted operating margin	20.9%	27.3%	27.0%	25.7%	25.4%	18.2%	21.1%	22.5%	20.3%	20.6%	23.5%
売上高対前年比 Revenue (YoY)						8.0%	1.8%	6.5%	8.6%	6.2%	9.1%
営業利益対前年比 Operating profit (YoY)						-16.6%	-	-25.1%	-50.0%	-55.5%	125.0%

■ ESD 地域別売上高 / Revenue by Region of ESD

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
日本 Japan	14,914	18,059	15,318	22,181	70,472	16,142	18,589	16,242	20,919	71,892
北米 North America	44,432	50,948	50,854	51,900	198,134	45,822	50,968	54,534	65,241	216,565
欧州 Europe	30,993	31,034	34,968	37,312	134,307	31,070	31,581	39,244	44,036	145,931
中国 China	12,388	24,100	22,625	23,793	82,906	17,415	23,391	18,673	15,471	74,950
アジア・オセアニア Asia and Oceania	11,195	13,448	13,186	14,062	51,891	13,389	14,899	14,100	16,591	58,979
その他 Others	2,935	4,026	3,567	3,585	14,113	3,300	4,302	5,655	5,043	18,300
合計 Total	116,857	141,615	140,518	152,833	551,823	127,138	143,730	148,448	167,301	586,617

■ TSD 地域別売上高 / Revenue by Region of TSD

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
日本 Japan	10,781	11,654	11,698	12,037	46,170	10,925	10,988	12,249	10,333	44,495
北米 North America	28,654	31,575	32,173	31,472	123,874	30,351	32,892	34,504	36,919	134,666
欧州 Europe	19,261	18,830	21,708	22,612	82,411	20,498	20,516	23,604	26,095	90,714
中国 China	6,836	10,160	7,451	9,700	34,147	7,010	8,935	7,178	7,625	30,748
アジア・オセアニア Asia and Oceania	5,469	6,832	6,513	6,729	25,543	6,805	7,355	7,554	7,183	28,897
その他 Others	1,364	1,519	1,464	1,715	6,062	1,567	1,856	2,439	1,950	7,811
合計 Total	72,365	80,570	81,007	84,265	318,207	77,156	82,542	87,528	90,105	337,331

■ 医療分野 地域別売上高 / Revenue by Region of Medical Business

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
日本 Japan	25,695	29,713	27,016	34,218	116,642	27,067	29,577	28,491	31,252	116,387
北米 North America	73,086	82,523	83,027	83,372	322,008	76,173	83,860	89,038	102,160	351,231
欧州 Europe	50,254	49,864	56,676	59,924	216,718	51,568	52,097	62,848	70,131	236,645
中国 China	19,224	34,260	30,076	33,493	117,053	24,425	32,326	25,851	23,096	105,698
アジア・オセアニア Asia and Oceania	16,664	20,280	19,699	20,791	77,434	20,194	22,254	21,654	23,774	87,876
その他 Others	4,299	5,545	5,031	5,300	20,175	4,867	6,158	8,094	6,993	26,111
合計 Total	189,222	222,185	221,525	237,098	870,030	204,294	226,272	235,976	257,406	923,948

■ サブセグメント別売上占有率 / Sub-segment Sales Ratio

	YTD
ESD	
消化器内視鏡 GI Endoscopy	約 Approx. 55 %
外科内視鏡 Surgical Endoscopy	約 Approx. 10 %
医療サービス Medical Service	約 Approx. 35 %
TSD	
消化器科処置具 GI EndoTherapy	約 Approx. 30 %
泌尿器科 Urology	約 Approx. 35 %
呼吸器科 Respiratory	約 Approx. 15 %
その他の治療領域 Other Therapeutic Areas	約 Approx. 20 %

* 四捨五入のため、合計値が100%にならないことがあります。 / Due to rounding, the total may not add up to 100%.

■地域別成長率（為替影響調整後） /

Growth Rate by Region (After Foreign Exchange Adjustment)

		FY2023					FY2024				
		Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
ESD	日本	10%	2%	-2%	16%	7%	8%	3%	6%	-6%	2%
	Japan	(10%)	(2%)	(-2%)	(16%)	(7%)	(8%)	(3%)	(6%)	(-6%)	(2%)
	北米	19%	29%	32%	13%	23%	3%	0%	7%	26%	9%
	North America	(0%)	(3%)	(7%)	(-1%)	(2%)	(-3%)	(-4%)	(3%)	(13%)	(2%)
	欧州	24%	5%	12%	19%	15%	0%	2%	12%	18%	9%
	Europe	(14%)	(-6%)	(-1%)	(10%)	(4%)	(-6%)	(-7%)	(4%)	(5%)	(-0%)
	中国	-10%	14%	57%	25%	21%	41%	-3%	-17%	-35%	-10%
	China	(-23%)	(-4%)	(38%)	(15%)	(6%)	(40%)	(-2%)	(-20%)	(-40%)	(-12%)
	アジア・オセアニア	30%	29%	26%	38%	31%	20%	11%	7%	18%	14%
	Asia and Oceania	(21%)	(16%)	(14%)	(28%)	(20%)	(18%)	(7%)	(2%)	(10%)	(9%)
	分野計	17%	17%	24%	20%	20%	9%	1%	6%	9%	6%
Total	(5%)	(1%)	(8%)	(10%)	(6%)	(5%)	(-3%)	(1%)	(0%)	(1%)	
TSD	日本	6%	-2%	-1%	10%	3%	1%	-6%	5%	-14%	-4%
	Japan	(6%)	(-2%)	(-1%)	(10%)	(3%)	(1%)	(-6%)	(5%)	(-14%)	(-4%)
	北米	20%	25%	28%	22%	24%	6%	4%	7%	17%	9%
	North America	(1%)	(0%)	(3%)	(7%)	(3%)	(0%)	(0%)	(3%)	(5%)	(2%)
	欧州	16%	16%	8%	14%	13%	6%	9%	9%	15%	10%
	Europe	(9%)	(5%)	(-4%)	(5%)	(3%)	(-1%)	(-2%)	(1%)	(3%)	(1%)
	中国	-2%	4%	11%	6%	5%	3%	-12%	-4%	-21%	-10%
	China	(-16%)	(-13%)	(-3%)	(-2%)	(-9%)	(2%)	(-11%)	(-7%)	(-27%)	(-12%)
	アジア・オセアニア	5%	30%	18%	30%	21%	24%	8%	16%	7%	13%
	Asia and Oceania	(-2%)	(18%)	(8%)	(21%)	(11%)	(23%)	(4%)	(10%)	(-0%)	(8%)
	分野計	14%	16%	15%	17%	15%	7%	2%	8%	7%	6%
Total	(2%)	(1%)	(0%)	(7%)	(3%)	(2%)	(-2%)	(3%)	(-3%)	(0%)	
医療分野 Medical Business	日本	8%	0%	-2%	14%	5%	5%	0%	5%	-9%	-0%
	Japan	(8%)	(0%)	(-2%)	(14%)	(5%)	(5%)	(0%)	(5%)	(-9%)	(-0%)
	北米	19%	28%	30%	16%	23%	4%	2%	7%	23%	9%
	North America	(1%)	(2%)	(5%)	(2%)	(2%)	(-1%)	(-3%)	(3%)	(10%)	(2%)
	欧州	21%	9%	10%	17%	14%	3%	4%	11%	17%	9%
	Europe	(12%)	(-2%)	(-2%)	(8%)	(4%)	(-4%)	(-5%)	(3%)	(5%)	(0%)
	中国	-7%	11%	42%	19%	16%	27%	-6%	-14%	-31%	-10%
	China	(-20%)	(-7%)	(25%)	(10%)	(2%)	(27%)	(-5%)	(-17%)	(-37%)	(-12%)
	アジア・オセアニア	21%	30%	23%	35%	27%	21%	10%	10%	14%	13%
	Asia and Oceania	(12%)	(17%)	(12%)	(25%)	(17%)	(19%)	(6%)	(5%)	(7%)	(9%)
	分野計	16%	17%	21%	19%	18%	8%	2%	7%	9%	6%
Total	(4%)	(1%)	(5%)	(9%)	(5%)	(4%)	(-2%)	(2%)	(-1%)	(0%)	

* () は為替影響調整後の成長率です。 / () :Growth rate after foreign exchange adjustment

■サブセグメント別成長率（為替影響調整後） /

Growth Rate by Sub-segment (After Foreign Exchange Adjustment)

		FY2023					FY2024				
		Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
ESD	消化器内視鏡	18%	17%	27%	19%	20%	3%	-5%	1%	9%	2%
	GI Endoscopy	(5%)	(1%)	(10%)	(9%)	(6%)	(0%)	(-8%)	(-3%)	(0%)	(-3%)
	外科内視鏡	11%	4%	7%	33%	14%	24%	-2%	6%	-10%	2%
	Surgical Endoscopy	(-1%)	(-10%)	(-7%)	(22%)	(2%)	(19%)	(-5%)	(1%)	(-16%)	(-3%)
	医療サービス	17%	25%	27%	15%	21%	13%	14%	14%	21%	16%
	Medical Service	(5%)	(8%)	(10%)	(5%)	(7%)	(8%)	(8%)	(8%)	(10%)	(8%)
	分野計	17%	17%	24%	20%	20%	9%	1%	6%	9%	6%
Total	(5%)	(1%)	(8%)	(10%)	(6%)	(5%)	(-3%)	(1%)	(0%)	(1%)	
TSD	消化器科処置具	14%	15%	12%	17%	14%	9%	11%	14%	14%	12%
	GI EndoTherapy	(5%)	(3%)	(2%)	(9%)	(5%)	(5%)	(6%)	(9%)	(5%)	(6%)
	泌尿器科	18%	24%	22%	22%	22%	8%	1%	3%	13%	6%
	Urology	(4%)	(4%)	(3%)	(10%)	(6%)	(2%)	(-4%)	(-2%)	(2%)	(-1%)
	呼吸器科	7%	9%	14%	11%	10%	2%	2%	2%	5%	3%
	Respiratory	(-5%)	(-7%)	(-2%)	(2%)	(-3%)	(-2%)	(-2%)	(-3%)	(-5%)	(-3%)
	その他の治療領域	12%	12%	8%	16%	12%	5%	-5%	12%	-8%	1%
	Other Therapeutic Areas	(2%)	(-1%)	(-5%)	(7%)	(1%)	(1%)	(-9%)	(7%)	(-16%)	(-5%)
分野計	14%	16%	15%	17%	15%	7%	2%	8%	7%	6%	
Total	(2%)	(1%)	(0%)	(7%)	(3%)	(2%)	(-2%)	(3%)	(-3%)	(0%)	

* () は為替影響調整後の成長率です。 / () :Growth rate after foreign exchange adjustment

2. セグメント別情報 / Information by Business Segment

(2) その他 / Others

■損益 / Revenue and Operating profit

百万円 (¥ million)	FY2023					FY2024					FY2025 Forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	
売上高 Revenue	3,043	2,610	2,960	3,280	11,893	3,429	2,650	3,093	3,090	12,262	13,000
営業損益 Operating profit (loss)	-296	-492	-129	3	-914	-141	1,141	-29	-8,780	-7,809	1,000
その他の損益 Other income and expenses	0	-8	-26	6	-28	-144	1,154	-1	-8,723	-7,714	-
営業利益率 Operating profit margin	-	-	-	-	-	-	43.1%	-	-	-	7.7%
売上高対前年比 Revenue (YoY)						12.7%	1.5%	4.5%	-5.8%	3.1%	6.0%
営業利益対前年比 Operating profit (YoY)						-	-	-	-	-	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

■地域別売上高 / Revenue by Region

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
日本 Japan	1,603	1,364	1,357	1,550	5,874	1,511	1,300	1,085	1,232	5,128
北米 North America	40	34	30	55	159	67	15	11	13	106
欧州 Europe	1,321	1,103	1,419	1,603	5,446	1,421	1,295	1,660	1,804	6,180
中国 China	7	14	10	10	41	310	7	316	10	643
アジア・オセアニア Asia and Oceania	72	95	144	62	373	120	32	22	31	205
その他 Others	-	-	-	-	-	-	-	-	-	-
合計 Total	3,043	2,610	2,960	3,280	11,893	3,429	2,649	3,094	3,090	12,262

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

(3) 全社消去 / Corporate expenses

■損益 / Revenue and Operating profit

百万円 (¥ million)	FY2023					FY2024					FY2025 Forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	
売上高 Revenue	-	-	-	-	-	-	-	-	-	-	-
営業損益 Operating profit (loss)	6,626	-10,922	-11,034	-13,608	-28,938	-9,241	-9,337	-10,762	-15,471	-44,811	-40,500
その他の損益 Other income and expenses	16,202	-412	-152	-1,379	14,259	-358	44	-1,391	-4,609	-6,314	-1,500

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

(4) 非継続事業 (科学事業) / Discontinued Operation (Scientific Solutions Business)

■損益 / Revenue and Operating profit

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
売上高 Revenue	21,795	30,949	38,267	44,410	135,421	-	-	-	-	-
営業損益 Operating profit (loss)	-3,745	-1,138	6,364	5,554	7,035	347,628	554	-68	162	348,276
その他の損益 Other income and expenses	-2,336	-2,609	-3,309	-2,726	-10,980	348,125	445	-69	19	348,520
営業利益率 Operating profit margin	-	-	16.6%	12.5%	5.2%	-	-	-	-	-

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。/

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

*2023年4月に非継続事業 (エビデント) の全株式の譲渡が完了したことに伴い、本株式譲渡に係る譲渡益をFY2024Q1に計上しています。/

Since all shares of discontinued operation (Evident) were transferred in April 2023, a gain on this share transfer was recorded in FY2024Q1.

3. 投資他 / Expenditures etc

■ 連結 / Consolidated

百万円 (¥ million)	FY2023					FY2024					FY2025 Forecast
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	
減価償却費 Depreciation and amortization	15,766	16,817	16,524	14,485	63,592	16,613	16,281	16,241	16,805	65,940	68,000
資本的支出 Capital expenditures	11,429	18,066	19,409	23,119	72,023	18,864	15,351	19,518	26,994	80,727	90,000
研究開発支出 R&D expenditures	16,965	19,127	15,333	25,441	76,866	17,895	20,793	22,277	25,403	86,368	97,000
開発費資産化 Capitalization of R&D expenditures	1,655	3,908	3,268	3,748	12,579	2,656	3,575	4,022	5,321	15,574	18,000

*上表の数値は継続事業の金額を表示しています。 / Amounts in the above table are related to continuing operations only.

■ ESD

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
減価償却費 Depreciation and amortization	9,167	9,947	10,157	8,224	37,495	10,276	10,261	10,361	10,603	41,501
資本的支出 Capital expenditures	6,749	11,393	11,996	12,863	43,001	11,821	10,196	12,960	15,697	50,674
研究開発支出 R&D expenditures	8,861	10,800	8,498	16,114	44,273	10,178	12,635	13,490	15,721	52,024

■ TSD

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
減価償却費 Depreciation and amortization	4,793	4,846	4,874	4,646	19,159	4,683	4,551	4,347	4,603	18,184
資本的支出 Capital expenditures	3,119	3,355	3,849	5,531	15,854	3,721	4,373	4,179	7,022	19,295
研究開発支出 R&D expenditures	5,198	5,502	4,722	7,303	22,725	5,635	6,270	6,804	7,180	25,889

■ 医療分野 / Medical Business

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
減価償却費 Depreciation and amortization	13,960	14,793	15,031	12,870	56,654	14,959	14,812	14,708	15,206	59,685
資本的支出 Capital expenditures	9,868	14,748	15,845	18,394	58,855	15,542	14,569	17,139	22,719	69,969
研究開発支出 R&D expenditures	14,059	16,302	13,220	23,417	66,998	15,813	18,905	20,294	22,901	77,913

■ その他・全社消去 / Others, Corporate expenses

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
減価償却費 Depreciation and amortization	1,806	2,024	1,493	1,615	6,938	1,654	1,469	1,533	1,599	6,255
資本的支出 Capital expenditures	1,561	3,318	3,564	4,725	13,168	3,322	782	2,379	4,275	10,758
研究開発支出 R&D expenditures	2,906	2,825	2,113	2,024	9,868	2,082	1,888	1,983	2,502	8,455

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、減価償却費及び資本的支出のFY2023Q1の数値も組み替えて表示しています。 /

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for "depreciation and amortization" and "capital expenditures" for FY21

4. 連結キャッシュ・フロー計算書 / Consolidated statement of cash flows

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
営業キャッシュ・フロー Cash flows from operating activities	-26,860	33,167	48,636	43,547	98,490	-53,112	41,335	-1,084	55,226	42,365
投資キャッシュ・フロー Cash flows from investing activities	5,198	-20,851	-22,207	-20,554	-58,414	426,988	-14,287	-21,256	-31,453	359,992
フリー・キャッシュ・フロー Free cash flow	-21,662	12,316	26,429	22,993	40,076	373,876	27,048	-22,340	23,773	402,357
調整後フリー・キャッシュ・フロー Adjusted Free cash flow	-20,237	15,445	47,204	42,893	85,305	-10,266	27,961	13,303	39,907	70,905
財務キャッシュ・フロー Cash flows from financing activities	-21,748	-13,704	-76,982	-30,744	-143,178	-25,888	-99,534	-115,363	-35,225	-276,010

* FY2023Q2より科学事業を非継続事業に分類したことに伴い、FY2023Q1の数値も組み替えて表示しています。 /

From FY2023Q2, Scientific Solutions Business has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2023Q1.

*調整後フリー・キャッシュ・フローの主な特殊要因はプレゼンテーションを参照ください。 / Please refer to the presentation for the major adjusted items of adjusted free cash flow.

なお、非継続事業からのキャッシュ・フローは以下の通り / Cash flows from discontinued operation are as below.

百万円 (¥ million)	FY2023					FY2024				
	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY	Q1 QTD	Q2 QTD	Q3 QTD	Q4 QTD	FY
営業キャッシュ・フロー Cash flows from operating activities	-9,871	-1,087	-2,693	500	-13,151	-57,303	-364	-61	159	-57,569
投資キャッシュ・フロー Cash flows from investing activities	-4,435	-1,582	-2,195	-3,513	-11,725	436,835	-2,937	-2,807	-0	431,091
財務キャッシュ・フロー Cash flows from financing activities	-416	-623	-327	-1,525	-2,891	-	-	-	-	-

5. 連結財政状態計算書 / Consolidated statement of financial position

百万円 (¥ million)	FY2023				FY2024			
	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31
資産 Assets	<u>1,433,466</u>	<u>1,486,123</u>	<u>1,392,608</u>	<u>1,508,701</u>	<u>1,688,272</u>	<u>1,617,765</u>	<u>1,468,078</u>	<u>1,534,216</u>
流動資産 Current assets	723,090	791,579	722,541	726,357	964,843	921,789	788,140	800,340
現金及び現金同等物 Cash and cash equivalents	286,412	255,765	175,748	169,329	558,722	488,160	348,572	340,933
棚卸資産 Inventories	186,875	171,182	170,912	162,994	177,487	183,430	186,517	190,030
売却目的で保有する資産 Assets held for sale	-	122,512	132,273	169,621	565	-	-	55
その他 Others	249,803	242,120	243,608	224,413	228,069	250,199	253,051	269,322
非流動資産 Non-current assets	710,376	694,544	670,067	782,344	723,429	695,976	679,938	733,876
負債 Liabilities	<u>851,311</u>	<u>842,027</u>	<u>787,020</u>	<u>867,467</u>	<u>781,348</u>	<u>790,233</u>	<u>718,196</u>	<u>777,030</u>
流動負債 Current liabilities	362,857	359,737	355,252	461,892	416,394	423,282	379,955	431,695
売却目的で保有する資産に直接関連する負債 Liabilities directly associated with assets held for sale	-	34,404	32,799	43,253	28	-	-	-
非流動負債 Non-current liabilities	488,454	482,290	431,768	405,575	364,954	366,951	338,241	345,335
資本 Equity	<u>582,155</u>	<u>644,096</u>	<u>605,588</u>	<u>641,234</u>	<u>906,924</u>	<u>827,532</u>	<u>749,882</u>	<u>757,186</u>
親会社の所有者に帰属する持分 Total equity attributable to owners of parent	581,125	643,024	604,468	640,085	905,904	827,532	749,882	757,186
その他 Others	1,030	1,072	1,120	1,149	1,020	-	-	-
有利子負債 Interest-bearing debt	394,794	389,798	352,735	340,057	345,966	348,414	304,679	299,616
純有利子負債 Net debt	108,382	134,033	176,987	170,728	-212,756	-139,746	-43,893	-41,317
自己資本比率 Equity ratio	40.5%	43.3%	43.4%	42.4%	53.7%	51.2%	51.1%	49.4%
有利子負債比率 Interest-bearing debt ratio	67.9%	60.6%	58.4%	53.1%	38.2%	42.1%	40.6%	39.6%

*2024年3月期第3四半期連結累計期間において、2022年12月に買収したOdin Medical Ltd.の取得資産と引受負債の公正価値を修正したことにより、2023年3月末の連結財政状態計算書を遡及修正しています。

In the 3Q of FY2024, the consolidated statement of financial position as of March 31, 2023 has been retrospectively adjusted due to the adjustment of the fair value of the assets acquired and liabilities assumed of Odin Medical Ltd. which was acquired in December 2022.

6. 会社概要 / Corporate Outline

■ 会社概要 / Corporate outline

2024年3月31日現在
As of Mar 31, 2024

会社名 Company name	オリンパス株式会社 Olympus Corporation
上場市場 Market	東京証券取引所プライム市場 Prime Market
銘柄コード Stock code	7733 ISIN: JP3201200007
設立年月日 Established	1919年10月12日 October 12, 1919
資本金（百万円） Capital (¥ million)	124,643
グループ会社数 Number of group companies	92（本社除く / excluding Olympus Corporation）
本社 Head Office	〒192-8507 東京都八王子市石川町2951 https://www.olympus.co.jp/ 2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan https://www.olympus-global.com/network/
事業場 Factory, R&D Center	八王子市（東京都）、上伊那郡（長野県）、西白河郡（福島県） Hachioji Tokyo Met., Kami Ina Nagano Pref., Nishi Shirakawa Fukushima Pref.
支店 Branch Offices	札幌、名古屋、大阪、広島、福岡、神戸 Sapporo, Nagoya, Osaka, Hiroshima, Fukuoka, Kobe
営業所 Sales Offices	新潟、松本、静岡、金沢、京都、岡山、松山、鹿児島 Niigata, Matsumoto, Shizuoka, Kanazawa, Kyoto, Okayama, Matsuyama, Kagoshima
海外拠点 Overseas Offices	アメリカ、ドイツ、イギリス、中国、シンガポールほか USA, Germany, UK, China, Singapore etc

■ 株式状況 / Stock information

2024年3月31日現在
As of Mar 31, 2024

発行可能株式総数（株） Total Number of Authorized Shares (Shares)	4,000,000,000
発行済株式総数（株） Number of Shares Issued (Shares)	1,215,146,700

■ 株式の分布状況 / Shareholder Distribution

2024年3月31日現在
As of Mar 31, 2024

	所有株式数 Number of shares	所有株式数の割合 Shareholders ratio
金融機関 Japanese financial institution	436,801,992	35.9%
証券会社 Japanese securities firms	40,753,839	3.4%
その他国内法人 Other Japanese corporations	34,039,488	2.8%
外国人 Foreign institutions and individuals	591,545,321	48.7%
個人・その他 Japanese individuals and others	62,491,153	5.1%
自己株式 Treasury stock	49,514,907	4.1%
合計 Total	1,215,146,700	100.0%

■ 従業員数 / Number of employees

	FY2023		FY2024							
	As of Mar 31		As of Jun 30		As of Sep 30		As of Dec 31		As of Mar 31	
合計（非継続事業含む） Total (Including discontinued operation)	32,805	(19,977)	28,527	(17,097)	28,712	(17,335)	28,903	(17,542)	28,838	(17,579)
内視鏡事業 Endoscopic Solutions Division	14,261	(7,766)	14,663	(7,916)	14,763	(8,045)	14,869	(8,197)	14,948	(8,361)
治療機器事業 Therapeutic Solutions Division	8,444	(6,042)	8,413	(6,033)	8,511	(6,126)	8,495	(6,122)	8,337	(6,000)
医療分野 Medical Business	22,705	(13,808)	23,076	(13,949)	23,274	(14,171)	23,364	(14,319)	23,285	(14,361)
その他、全社 Others, Corporate	5,976	(3,517)	5,451	(3,148)	5,438	(3,164)	5,539	(3,223)	5,553	(3,218)
非継続事業 Discontinued Operation	4,124	(2,652)	0	(0)	0	(0)	0	(0)	0	(0)

*（ ）は海外従業員数です。 /（ ）: Number of overseas employees

* FY2024Q1より、要員数の集計範囲を全社で統一したため一部地域の要員数に変更になり、FY2023Q4の従業員数を遡及して修正しています。また、FY2024Q4より、国内の一部組織における集計区分が変更になり、FY2024Q1からQ3までの従業員数を遡及して修正しています。 /

Due to the unification of aggregation range throughout the company from FY2024Q1, the number of personnel in some regions was changed. Accordingly, the figures for FY2023Q4 have been retroactively revised. In addition, the aggregation category of some Japanese organizations has been changed from FY2024Q4, and the figures from FY2024Q1 to FY2024Q3 has been retroactively revised.